P53 and Expression of Immunological Markers May Identify Early Stage Thyroid Tumors

Table 3

TP53 genetic alterations in PTC patients, according to histopathological subtypes and the mean p53 protein expression quantified with the automated cellular imaging system ACIS-III.

Histopathology of PTC (total of cases)	TP53 alteration							Expression of p53 protein
	Number of cases	Distribution of alleles	Nucleotide	Local	AA change	Mutation type	dbSNP ID	Mean	Median
CPTC (54)	43	16 CG/27 GG	C11117G	Intron 2	—	Intronic	rs1642785	65.70	77.22
	18	14 GC/04 CC	G11446C	Exon 4	R72P	Missense	rs1042522	62.48	74.40
	02	02 AG	A12708G	Exon 6	R213R	Silent	rs1800372	74.88	74.88
	04	04 CT	C13491T	Intron 7	—	Intronic	rs12947788	88.45	90.89
	01	01 AT	A17021T	Intron 10	—	Intronic	rs17880847	Unavailable tissue
	01	01 TG	T16987G	Éxon 10	S366A	Missense	rs17881470	94.80	—
FVPTC (23)	18	07 CG/11 GG	C11117G	Intron 2	—	Intronic	rs1642785	71.54	85.04
	01	01 CA	C11299A	Intron 3	—	Intronic	rs17883323	92.61	—
	08	05 GC/03 CC	G11446C	Exon 4	R72P	Missense	rs1042522	77.49	94.45
	01	01 AG	A12708G	Exon 6	R213R	Silent	rs1800372	59.59	—
	02	02 CT	C13491T	Intron 7	—	Intronic	rs12947788	52.71	52.71
	01	01 GA	G13925A	Intron 8	—	Intronic	—	95.66	—
TCVPTC (1)	01	01 GG	C11117G	Intron 2	—	Intronic	rs1642785	23,28	—